Rheumatoid Arthritis Therapy Reappraisal Strategies, Opportunities and Challenges

• Muut tekijät: Müller, Rüdiger (Toimittaja)
• Aineistotyyppi: Elektroninen Kirjan osa
• Kieli: englanti
• Julkaistu: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Aiheet: Medicine; rheumatoid arthritis; sleep; sleep disorders; pain; osteoporosis; fracture; fracture risk assessment tool; treat-to-target; certolizumab pegol; csDMARDs; glucocorticoids; intra-articular injections; DAS 28; ACR response; HAQ-DI; TNFα; golimumab; efficacy; tolerability; immunogenicity; methotrexate; posology; titration; oral route; subcutaneous route; bioavailability; effectiveness; periodontitis; periodontal disease; anti-citrullinated protein autoantibodies; rheumatoid factor; smoking; medication; Porphyromonas gingivalis; Rheumatoid arthritis; matrix metalloproteinase 3; infliximab; pharmacogenomics; anti-TNF; personalized medicine; baricitinib; disease-modifying antirheumatic drugs; pain perception; outcomes research; patient perspective; Rheumatoid Arthritis; therapy; DMARD; MTX; Tumor Necrosis Factor-Alpha Inhibitors; ankylosing spondylitis; biosimilar; switching; synovial fibroblasts; cytokine; osteoclast; herbal medicine; methylation; next-generation sequencing; recovery of function; fatigue; productivity; tofacitinib; oral; Th1.17; IL-17A; IFN-γ, CD73; adenosine; psoriatic arthritis; regulation; pseudoerosions; hand; foot; ultrasonography; radiography; computed tomography; magnetic resonance imaging; n/a
• Linkit: DOAB: download the publication; DOAB: description of the publication

Rheumatoid Arthritis (RA) is a chronic inflammatory disease leading to joint inflammation and destruction. Treatment of RA includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs), and oral or intraarticular (IA) glucocorticoids (GCs). All different classes...